Global Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Overview:
The minimal invasive glaucoma surgery (MIGS) procedures are expected to grow in the future due to an increase in the demand for surgery devices and government support such as favorable reimbursement policies and foreign direct investment provisions. High demand for minimally invasive glaucoma surgery devices due to various benefits such as reduced surgery time, shorter recovery period, affordability, and low risk of post-surgical complications, including hypotony. The surge in the number of glaucoma care initiatives conducted by the government and several non-governmental organizations is expected to have a positive impact on the adoption of advanced devices.
- Increased Number of Minimally Invasive Surgery Performed Around the Glob
- High Benefits of Minimally Invasive Surgeries
- Increase in Focus of Key Players in the Development of MIGS Stents
- Rise in the Demand for Combined Glaucoma and Cataract Surgeries
- Reimbursement Barriers regarding MIGS Devices
- Availability of alternative treatment methods
- Increased Research and Development Activities
- Growth Opportunities in Emerging Markets
- Growing Public-Private Initiatives to Support Research Activities on Minimally Invasive Surgical Instruments
- Dearth of skilled professionals
- Lack of Awareness about Glaucoma and Its Treatment Procedures in Underdeveloped Countries
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations.
Some of the key players profiled in the report are Alcon Inc. (Switzerland), Ellex Medical Lasers Ltd. (Australia), Glaukos Corporation (United States), Allergan Plc (United States), Santen Pharmaceutical Co., Ltd. (Japan), Lumenis (United States), Ivantis, Inc. (United States), SOLX, Inc (United States), iSTAR Medical ( Belgium), InnFocus Inc. (United States), Bausch & Lomb Inc. (United States), Neomedix Corporation (United States), IOPtima (Israel) and Abbott Medical Optics, Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like Topcon Corporation (Japan), New World Medical, Inc (United States) and Carl-Zeiss AG (Germany). Analyst at AMA Research see United States Players to retain maximum share of Global Minimally Invasive Glaucoma Surgery (MIGS) Devices market by 2026. Considering Market by , the sub-segment i.e. will boost the Minimally Invasive Glaucoma Surgery (MIGS) Devices market.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Minimally Invasive Glaucoma Surgery (MIGS) Devices market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Minimally Invasive Glaucoma Surgery (MIGS) Devices market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Minimally Invasive Glaucoma Surgery (MIGS) Devices, Suppliers of Minimally Invasive Glaucoma Surgery (MIGS) Devices, Wholesalers, Distributors, and Retailers of Minimally Invasive Glaucoma Surgery (MIGS) Devices, Healthcare Industry, Governmental Bodies and Research Firms.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.